Recommendations for planning and delivery of radical radiotherapy for localized urothelial carcinoma of the bladder

Khalifa, J.; Supiot, S.; Pignot, G.; Hennequin, Christophe; Blanchard, Pierre; Pasquier, David; Magné, Nicolas; Crevoisier, R. de; Graff-Cailleaud, Pierre; Riou, O.; Cabaillé, M.; Azria, D.; Latorzeff, I.; Créhange, G.; Chapet, O.; Rouprêt, Morgan; Belhomme, S.; Méjean, Arnaud; Culine, Stéphane; Sargos, P.

doi:10.1016/j.radonc.2021.06.011

Cited by 22 publications

(17 citation statements)

References 155 publications

(358 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another debated topic related to CRT treatment is the desirability of elective lymph node irradiation [13] . In a recent consensus meeting of the European Association of Urology and European Society of Medical Oncology, a majority of stakeholders preferred to electively irradiate PLNs in case of CRT [14] .…”

Section: Discussionmentioning

confidence: 99%

A Multicenter Retrospective Cohort Series of Muscle-invasive Bladder Cancer Patients Treated with Definitive Concurrent Chemoradiotherapy in Daily Practice

Ruiter

Kamp

Steenbergen

et al. 2022

European Urology Open Science

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

A Multicenter Retrospective Cohort Series of Muscle-invasive Bladder Cancer Patients Treated with Definitive Concurrent Chemoradiotherapy in Daily Practice

Ruiter

Kamp

Steenbergen

et al. 2022

European Urology Open Science

View full text Add to dashboard Cite

“…For delineation of RT target volumes in MIBC, use of anisotropic CTV to PTV margins are recommended [15] given it has been shown that inter-fraction motion of the target is anisotropic, with greatest amplitude of motion in the cranial and anterior directions [16] , [17] , [18] . Choice of the size of CTV to PTV expansion margin largely depends on setup, verification, and treatment techniques.…”

Section: Discussionmentioning

confidence: 99%

A retrospective review of the long-term outcomes of online adaptive radiation therapy and conventional radiation therapy for muscle invasive bladder cancer

Yeh

Bressel

Tai

et al. 2021

Clinical and Translational Radiation Oncology

View full text Add to dashboard Cite

show abstract

“…Среди значимых факторов риска распространения процесса на уретру были определены следующие: локализация опухоли в области шейки мочевого пузыря, мультифокальный характер роста и наличие Т is [62,63]. При наличии указанных неблагоприятных факторов рекомендуется включение предстательной железы в клинический объем облучения [32]. Подтвержденное результатами биопсии или клиническими данными поражение простатического отдела уретры рассматривается в качестве абсолютного показания к включению предстательной железы в объем облучения.…”

Section: рекомендации по проведению нхт при тмт: • выполнение нхт пер...unclassified

“…J. Kalifa и соавт. впервые сформулировали критерии, описывающие удовлетворительную функцию мочевого пузыря при планировании ТМТ [32] Возможность реализации химиолучевой терапии (ХЛТ) имеется у большинства больных МИРМП. Место и роль ТМТ в зависимости от различных клинических ситуаций наиболее полно представлены в актуальных сводных рекомендациях NCCN (2021) (табл.…”

unclassified

Guideline on trimodal therapy of bladder cancer (Nevskiy consensus 2021)

Novikov

Новиков

et al. 2022

Onkourologiâ

View full text Add to dashboard Cite

The aim of this work was to clarify and extend the existing clinical guidelines on organ-sparing treatment of muscleinvasive bladder cancer. The standard protocol of radical conservative treatment for muscle-invasive bladder cancer includes transurethral resection of the bladder, external beam radiotherapy with simultaneous chemotherapy (radiosensitization), which is usually referred to as trimodal therapy. The implementation of trimodal therapy into routine practice in Russia is limited due to the lack of distinct criteria for each of the stages. The involvement of surgeons, radiation oncologists, and chemotherapists, on the one hand, provides the required multidisciplinary approach to cancer treatment; on the other hand, it might impede the entire algorithm. To address this problem, specialists from the Department of Radiology (project moderators), Department of Cancer Urology, and Department of Chemotherapy of N.N. Petrov National Medical Research Center of Oncology under the auspices of Saint Petersburg Oncological Research Society formed a group of experts, including radiation oncologists, urologists, and chemotherapists from federal and local cancer (educational) institutions of Saint Petersburg who had an experience of treating muscle-invasive bladder cancer. The guideline was developed with the consideration of available guidelines published by leading professional associations of radiotherapy and oncology (urological), research articles, and own experience.

show abstract

Recommendations for planning and delivery of radical radiotherapy for localized urothelial carcinoma of the bladder

Cited by 22 publications

References 155 publications

A Multicenter Retrospective Cohort Series of Muscle-invasive Bladder Cancer Patients Treated with Definitive Concurrent Chemoradiotherapy in Daily Practice

A Multicenter Retrospective Cohort Series of Muscle-invasive Bladder Cancer Patients Treated with Definitive Concurrent Chemoradiotherapy in Daily Practice

A retrospective review of the long-term outcomes of online adaptive radiation therapy and conventional radiation therapy for muscle invasive bladder cancer

Guideline on trimodal therapy of bladder cancer (Nevskiy consensus 2021)

Contact Info

Product

Resources

About